{"organizations": [], "uuid": "01ed72bc7b04775e6c3d9b27ca9bf37155cb4d19", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-reports-q/brief-ironwood-pharmaceuticals-reports-q1-loss-per-share-of-0-29-idUSASC09YKC", "country": "US", "domain_rank": 408, "title": "BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T15:00:00.000+03:00", "replies_count": 0, "uuid": "01ed72bc7b04775e6c3d9b27ca9bf37155cb4d19"}, "author": "", "url": "https://www.reuters.com/article/brief-ironwood-pharmaceuticals-reports-q/brief-ironwood-pharmaceuticals-reports-q1-loss-per-share-of-0-29-idUSASC09YKC", "ord_in_thread": 0, "title": "BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "ironwood pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "allergan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29 Ironwood Pharmaceuticals Inc:\n* IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2018 INVESTOR UPDATE\n* Q1 NON-GAAP LOSS PER SHARE $0.27 * Q1 REVENUE $69 MILLION VERSUS I/B/E/S VIEW $79.1 MILLION\n* Q1 $-0.23 IW-3718 PHASE III PROGRAM EXPECTED TO INITIATE IN Q3 OF 2018\n* PHASE II SGC PROGRAMS, PRALICIGUAT AND OLINCIGUAT (IW-1701) CONTINUE TO PROGRESS\n* CO, ALLERGAN EXPECT TO INITIATE A SINGLE PHASE III TRIAL WITH LINZESS IN MID-2018\n* IRONWOOD - FOLLOWING SERIES OF MEETINGS WITH FDA, CO EXPECTS TO INITIATE 2 RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIALS FOR IW-3718 IN Q3 2018\n* ENDED Q1 2018 WITH ABOUT $194.4 MILLION CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES ", "external_links": [], "published": "2018-05-01T15:00:00.000+03:00", "crawled": "2018-05-01T15:19:44.000+03:00", "highlightTitle": ""}